Skip to main content
Stock Expert AI
Momentum Movers INTERMEDIATE ✨ AI Enhanced

Why did Regeneron stock rise? Shares jumped after a Q3 beat

8 min read Data as of 2 sources
REGN$927.89+13.33%Today, Nov 20, 2026: 95/100

AI-generated editorial content. For informational purposes only. Not financial advice.

REGN — Journal cover

Stock Expert AI data cover: figures from Financial Modeling Prep. Photo credit and licence on the image

Regeneron (REGN) stock rose 13.33% on Oct. 30, 2026, to 927.89 USD, and 14.09% over two sessions from the Oct. 28 close, after the company reported third-quarter results that beat Wall Street estimates. On the call, management said revenue growth came from Dupixent profit share, the eye drug EYLEA HD and the cancer drug Libtayo. Separately, our reading of the data is that operating margin reached a five-quarter high.

Figures are current as of the Oct. 30, 2026 quote and cover the third quarter ended Sept. 30, 2026, unless noted.

Key facts

  • Oct. 30, 2026: Shares closed at 927.89 USD, up 13.33% on the day. The 52-week range is 591.52-935.35 USD.
  • Q3 FY2026 (ended Sept. 30, 2026): Revenue was $5.12B, 36.3% higher than a year earlier. Analysts had estimated $4.58B.
  • Q3 FY2026 earnings per share: The reported figure was 20.07 versus a 16.51 estimate. Diluted EPS was 18.45, versus 13.62 a year earlier.
  • Q3 FY2026 net income: $1.95B, up 33.5% from a year earlier.
  • Q3 FY2026 operating margin: 40.0%, the highest of the last five quarters.
  • Next earnings date: Jan. 28, 2027 (EPS estimate 24.25, revenue estimate $5.75B).
MetricQ3 FY2026Q3 FY2025 (year-ago)
Revenue$5.12B$3.75B
Operating income$2.05B$1.03B
Net income$1.95B$1.46B
Diluted EPS18.4513.62

What happened

Regeneron reported on Oct. 30, 2026, and the stock reacted the same day. Revenue and EPS both came in above analyst estimates. Revenue beat by $531.5M, or 11.6%, and the reported EPS figure beat by $3.56, or 21.6%. CEO Leonard Schleifer said on the call: "This was an exceptional quarter by every measure." The call also covered pipeline updates, including CIDEB data, so we cannot say which item moved the shares.

Management named several revenue drivers on the call, which also show up in the segment data:

  • Dupixent and the Sanofi collaboration. Dupixent treats several inflammatory conditions. Sanofi sells it, and Regeneron earns a share of the profit. Collaboration revenue was $3.00B, against $1.97B a year earlier. Management said Sanofi-related revenue was a record, helped by Dupixent demand across its approved uses and by the completed repayment of a development balance in the second quarter. In plain terms, Regeneron now keeps more of each Dupixent dollar.
  • EYLEA HD. This high-dose eye injection grew strongly in the U.S. Management said physician demand rose from the prior quarter after label enhancements. It also said the original EYLEA is losing ground to competing biosimilars (cheaper copies of a biologic drug).
  • Libtayo. Management reported record global sales, helped by a newly approved use after surgery for a type of skin cancer. Schleifer said Libtayo is now on an annual run rate of approximately $2.2 billion.
  • Other revenue. The CFO said Ilaris royalty revenue included an approximately $60 million cumulative catch-up adjustment that will not recur in the fourth quarter.
Product revenue was $1.81B, up from $1.59B a year earlier. Collaboration revenue is where most of the growth came from.

Motley Fool coverage on Oct. 31 also highlighted early data for a liver-disease gene-silencing drug aimed at a target called CIDEB. Chief Scientific Officer George Yancopoulos said the approach targets a genetically validated pathway. Fuller details are planned for a November roundtable.

Why it matters for investors

Margins and cash flow both improved in Q3 FY2026. Here is the five-quarter picture and what it shows: profitability has climbed for two straight quarters, after a weak first quarter of 2026.

QuarterRevenueGross marginOperating marginFree cash flow
Q3 FY2025$3.75B86.1%27.3%$1.42B
Q4 FY2025$3.88B84.9%22.7%$922.0M
Q1 FY2026$3.61B81.4%17.8%$848.3M
Q2 FY2026$4.29B86.6%33.1%$334.3M
Q3 FY2026$5.12B88.8%40.0%$1.48B

Free cash flow is cash from operations minus capital spending. Operating cash flow was $1.78B in the latest quarter, versus $574.5M in the second quarter. Cash flow in this business can be uneven from quarter to quarter, as the second-quarter low shows. Management also said EYLEA HD and EYLEA benefited modestly from the timing of end-of-quarter shipments.

The balance sheet is strong. Regeneron held $9.30B in cash and short-term investments against $2.71B of debt. The CFO said the company ended the quarter with $16.2 billion of cash and marketable securities net of debt, a figure that includes marketable securities. In Q3 it spent $399.7M on buybacks and $95.7M on dividends. Management said full-year 2026 share repurchases would be approximately $3 billion.

Valuation versus peers. On trailing 12-month numbers, Regeneron trades at a P/E of 19.76 and a net margin of 28.5%. The peers in our data:

  • Amgen (AMGN): P/E 28.73, net margin 22.9%.
  • AstraZeneca (AZN): P/E 26.25, net margin 17.7%.
  • Biogen (BIIB): P/E 107.47, net margin 3.4%.
Regeneron's P/E is lower than Amgen's and AstraZeneca's while its net margin is higher than both. A P/E is the share price divided by a year of earnings. It tells you how much the market pays for each dollar of profit. The trailing figure still includes weaker quarters, so it can look different once the strong ones fully roll in.

Analysts. The consensus rating is "Buy": 35 buy and 14 hold ratings among 49, with no sells. The average analyst price target is 859.63 USD (median 860.00), with a range of 750.00 to 1030.00 USD. The latest price is above the average target. Among recent actions, JP Morgan kept Overweight and Citigroup kept Neutral on Oct. 30, and UBS upgraded to Buy on Oct. 15.

Our MoonshotScore. Stock Expert AI's MoonshotScore V2 for REGN is 94.7, rated Exceptional. The pillars, scored relative to the sector, are:

  • Safety: 94
  • Quality: 93
  • Momentum: 90
  • Growth: 71
  • Valuation: 58
The valuation pillar is the weakest, which fits the idea that the share price already reflects good news. The financial strength scores are solid: Piotroski 6 out of 9 and Altman Z 7.70.

What could go wrong

Management named several headwinds on the call:

  • EYLEA pressure. U.S. sales of the original EYLEA fell as 2 mg biosimilars arrived. EYLEA HD faces pricing pressure. The company expects fourth-quarter EYLEA (non-HD) demand to decline by the low-to-mid teens in percent terms.
  • Timing and one-offs. The CFO said the approximately $60 million Ilaris cumulative royalty catch-up adjustment will not recur in the fourth quarter. Marion McCourt said EYLEA HD and EYLEA "benefited modestly" from shipment timing.
  • Rising costs. Management expects 2027 research spending to grow by a mid-teens percentage and the tax rate to rise by roughly 100 to 200 basis points (1 to 2 percentage points).
  • Execution. When an analyst raised the risk of a broad product lineup, Schleifer said "it does not mean we are gonna be perfect."
Two further points are our own observations, not management's:
  • Dependence on Dupixent. Results lean heavily on Dupixent growth and on Sanofi's economics.
  • Insider selling. Among the 30 most recent insider filings, those dated in the last 90 days show 27 sales and no open-market purchases. Insider sales are common and can have many reasons, but it is a data point.
Also note the move itself: a 13.33% one-day gain pushed the price near the top of its 52-week range, so expectations are higher going into the next report.

What to watch next

  • Fourth-quarter guidance. Management expects EYLEA HD sequential growth of approximately 10% and full-year EYLEA HD growth of over 50%. It also expects the full $1 billion Sanofi upfront payment to be recognized in Q4.
  • The next earnings report on Jan. 28, 2027, with an EPS estimate of 24.25 and a revenue estimate of $5.75B.
  • Margins. Whether the 40.0% operating margin holds once one-time items fall away.
  • The November liver-disease roundtable, where the company plans to share more detail on CIDEB.
  • Analyst estimates. Consensus for the quarter ending June 30, 2028 is revenue of $5.43B and EPS of 20.84, from 5 analysts. Watch whether estimates move after this report.

Frequently asked questions

Q: Why did Regeneron stock go up on Oct. 30, 2026?

Regeneron shares rose 13.33% on Oct. 30, 2026 after the company reported third-quarter results that beat analyst estimates for both revenue and earnings. On the call, management pointed to record Dupixent-related collaboration revenue, strong EYLEA HD sales and record Libtayo sales as drivers of revenue growth. The call also covered pipeline updates, and no source here explains the share move itself.

Q: Is Regeneron stock expensive after the jump?

On trailing 12-month earnings, REGN's P/E of 19.76 is lower than Amgen's 28.73 and AstraZeneca's 26.25. The price of 927.89 USD is above the average analyst target of 859.63 USD, and our MoonshotScore valuation pillar is the lowest at 58. Whether that is fair depends on whether the recent profit level lasts. This is not investment advice.

Q: What are the biggest risks for Regeneron?

Management named competition and pricing pressure on EYLEA, an approximately $60 million Ilaris catch-up that will not recur, higher 2027 research spending and a higher tax rate. Our own observation is that results also depend heavily on Dupixent and the Sanofi partnership.

This is educational content, not investment advice. Past performance does not guarantee future results.

What to watch next

  1. The next earnings report on Jan. 28, 2027, with an EPS estimate of 24.25 and a revenue estimate of $5.75B.
  2. Analyst estimates. Consensus for the quarter ending June 30, 2028 is revenue of $5.43B and EPS of 20.84, from 5 analysts. Watch whether estimates move after this report.

REGN on Stock Expert AI

MoonshotScore 95/100 Nov 20, 2026

A 0-100 score built from five sections.

  • Quality92
  • Safety96
  • Valuation54
  • Growth80
  • Momentum93
🎯

MoonshotScore AI Ratings

Each stock is scored 0-100 on five pillars: Business Quality, Financial Safety, Valuation, Growth Durability and Momentum. A story quotes the score of the day it was written.

REGN Today, Nov 20, 2026: 95/100

Related Tickers

earningsbiotechnology

Sources

Related Sectors & Industries

Related 2026 Trends

Next story

Biotech Brief Novo Nordisk NVO reports Nov. 4: a low P/E, but profit swings by the quarter 9 min readNVO
👁 Editorial Transparency
🧠Content generated by AI editorial engine
👤Stock Expert AI Research is an AI editorial voice of Stock Expert AI
✅Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
🛡Financial Modeling Prep (FMP)
🕑Last updated:

Get the week's earnings in one Thursday email

The S&P 500 companies on that week's earnings calendar, each with its current MoonshotScore, plus the week's Journal research. Free, one email a week, with an unsubscribe link in every issue.

We send one confirmation email first and nothing else until you click its link (it works for 7 days). After that, the Weekly only. Your address is not sold or shared. Newsletter details · Free guide: How to read a MoonshotScore · Privacy Policy


Explore More Market Intelligence

Evidence & Sources

  • Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
  • MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). Weights are rescaled to 100 when all five pillars have data: 28.3%, 21.7%, 19.6%, 17.4% and 13.0% of the score. It reads no news-sentiment or analyst data, and it is not a probability of future returns.
  • Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
  • Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
  • This page is educational and does not constitute investment advice.
  • Numbers come from market data providers (FMP); AI writes the plain-English explanations around them, which should be verified with independent research.